BackHemab Therapeutics Holdings Common Stock Overview

Hemab Therapeutics Holdings Common Stock Receivables

Track Hemab Therapeutics Holdings Common Stock's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Hemab Therapeutics Holdings Common Stock Receivables History

Loading

Hemab Therapeutics Holdings Common Stock vs. peers: Receivables Comparison

Loading

Hemab Therapeutics Holdings Common Stock Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Hemab Therapeutics Holdings Common Stock (COAG) FAQ

Hemab Therapeutics Holdings Common Stock's receivables stands at $0 as of June 2026. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether Hemab Therapeutics Holdings Common Stock's receivables is expanding or contracting. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Hemab Therapeutics Holdings Common Stock's receivables evolved across reporting periods, while the comparison chart places COAG next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Hemab Therapeutics Holdings Common Stock's reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.